InMode Ltd.
INMD Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2017–FY2025
Last close · Oct 23, 2026
$13.97
0.6%What InMode Ltd. does
No business description yet.
- Legal name
- InMode Ltd.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 10, 2026
- Accession · CIK
- 0001178913-26-000377
0001742692
Revenue and margins
InMode Ltd. had $370M of revenue in fiscal 2025, down 6.2% on the year before.
Net income and earnings per share
From fiscal 2017 to 2025, diluted EPS grew 23.8% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $84.3M in fiscal 2025, 22.7% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
InMode Ltd. returned $127M to shareholders in fiscal 2025, 151% of free cash flow. The diluted share count fell 18.8%.
Balance sheet
Cash, debt and the ratios that show how comfortably InMode Ltd. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $363M | $472M | $518M | $423M | $386M |
| Current ratio | 9.1x | 7.7x | 13.2x | 10.2x | 9.9x |
| Quick ratio | 8.7x | 7.2x | 12.5x | 9.4x | 8.8x |
| Total assets | $479M | $644M | $863M | $786M | $766M |
| Total liabilities | $62.7M | $89.8M | $75.9M | $81.9M | $83.2M |
| Shareholders' equity | $416M | $555M | $787M | $704M | $683M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | — | — | ✓ | ✕ | ✓ | ✕ | ✕ | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ |
| Debt fell relative to assets | — | — | — | — | — | — | — | — | — |
| Current ratio rose | — | — | ✓ | ✓ | ✓ | ✕ | ✓ | ✕ | ✕ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ | ✓ | ✕ | ✓ | ✓ |
| Gross margin rose | — | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Revenue rose relative to assets | — | — | ✕ | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ |
| F-score | — / 3 | — / 5 | 6 / 8 | 4 / 8 | 6 / 8 | 4 / 8 | 3 / 8 | 4 / 8 | 3 / 8 |
| Accruals ratio | — | −17.9% | −0.7% | −1.6% | −2.6% | −3.6% | 2.8% | 5.9% | 1.1% |
| Altman Z'' | — | 8.51 | 13.46 | 15.78 | 17.32 | 16.63 | 20.97 | 19.00 | 18.86 |
9 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $53.5M | $100M | $156M | $206M | $358M | $454M | $492M | $395M | $370M |
| Net interest income | — | — | — | — | −$1.2M | $1.2M | $4.7M | — | — |
| Gross profit | $44.4M | $85.1M | $136M | $175M | $304M | $381M | $411M | $317M | $291M |
| Research and development | $2.6M | $4.2M | $5.7M | $9.5M | $9.5M | $12.4M | $13.4M | $13.1M | $13.3M |
| Operating income | $9.0M | $23.5M | $59.6M | $72.8M | $167M | $198M | $196M | $113M | $85.4M |
| Pretax income | $9.8M | $23.6M | $62.0M | $76.1M | $168M | $201M | $217M | $143M | $110M |
| Income tax | $1.0M | $1.3M | $0.9M | $1.1M | $2.9M | $39.9M | $19.3M | −$37.8M | $16.5M |
| Net income | $8.8M | $22.4M | $61.1M | $75.0M | $165M | $162M | $198M | $181M | $93.8M |
| Diluted EPS | $0.26 | $0.62 | $0.80 | $0.89 | $1.92 | $1.89 | $2.30 | $2.25 | $1.43 |
| Diluted shares | 0.03B | 0.04B | 0.08B | 0.08B | 0.09B | 0.09B | 0.09B | 0.08B | 0.07B |
| Cash flow | |||||||||
| Cash from operations | $14.6M | $36.9M | $62.2M | $79.2M | $175M | $182M | $177M | $133M | $85.3M |
| Capital expenditure | $0.2M | $0.4M | $0.7M | $0.5M | $0.9M | $1.6M | $0.7M | $0.7M | $1.0M |
| Free cash flow | $14.4M | $36.5M | $61.5M | $78.8M | $174M | $180M | $176M | $132M | $84.3M |
| Depreciation and amortization | $0.2M | $0.2M | $0.3M | $0.4M | $0.5M | $0.7M | $0.6M | $0.7M | $0.7M |
| Stock-based compensation | $2.4M | $1.9M | $1.6M | $12.8M | $12.0M | $24.5M | $23.6M | $16.6M | $11.1M |
| Share buybacks | — | — | — | $17.2M | $35.4M | $42.6M | $0.0M | $285M | $127M |
| Dividends and buybacks | — | — | — | $17.2M | $35.4M | $42.6M | $0.0M | $285M | $127M |
| Balance sheet | |||||||||
| Cash and short-term investments | $17.6M | $51.3M | $165M | $211M | $363M | $472M | $518M | $423M | $386M |
| Current assets | — | $77.8M | $213M | $290M | $470M | $629M | $845M | $714M | $699M |
| Current liabilities | — | $29.4M | $32.5M | $35.0M | $51.9M | $82.0M | $64.1M | $69.9M | $70.7M |
| Inventory | — | $7.0M | $9.4M | $15.0M | $21.0M | $39.9M | $45.1M | $59.5M | $74.1M |
| Property and equipment, net | — | $0.5M | $0.9M | $1.0M | $1.4M | $2.3M | $2.4M | $2.3M | $2.6M |
| Total assets | — | $81.1M | $218M | $296M | $479M | $644M | $863M | $786M | $766M |
| Total liabilities | — | $34.2M | $38.6M | $40.3M | $62.7M | $89.8M | $75.9M | $81.9M | $83.2M |
| Shareholders' equity | $19.5M | $43.3M | $176M | $254M | $416M | $555M | $787M | $704M | $683M |
| Margins | |||||||||
| Gross margin | 83.1% | 85.0% | 87.1% | 85.0% | 85.0% | 83.8% | 83.6% | 80.3% | 78.5% |
| Operating margin | 16.7% | 23.5% | 38.1% | 35.3% | 46.8% | 43.6% | 39.8% | 28.5% | 23.0% |
| EBITDA margin | 17.1% | 23.6% | 38.3% | 35.5% | 47.0% | 43.7% | 39.9% | 28.7% | 23.2% |
| Net margin | 16.5% | 22.3% | 39.1% | 36.4% | 46.1% | 35.6% | 40.2% | 45.9% | 25.3% |
| FCF margin | 27.0% | 36.4% | 39.3% | 38.2% | 48.6% | 39.6% | 35.8% | 33.4% | 22.7% |
| Net interest share of revenue | — | — | — | — | −0.3% | 0.3% | 1.0% | — | — |
| Returns | |||||||||
| Return on capital employed | — | 45.5% | 32.1% | 27.9% | 39.3% | 35.2% | 24.5% | 15.7% | 12.3% |
| Return on equity | 45.3% | 71.3% | 55.8% | 34.9% | 49.3% | 33.3% | 29.5% | 24.3% | 13.5% |
| Return on assets | — | 27.6% | 40.8% | 29.2% | 42.6% | 28.8% | 26.3% | 22.0% | 12.1% |
| Return on tangible equity | 45.3% | 51.7% | 34.7% | 29.5% | 39.7% | 29.1% | 25.1% | 25.8% | 13.7% |
| Growth | |||||||||
| Revenue growth | — | 87.4% | 56.1% | 31.8% | 73.5% | 27.0% | 8.3% | −19.8% | −6.2% |
| Net income growth | — | 153.7% | 173.3% | 22.7% | 119.9% | −2.1% | 22.5% | −8.4% | −48.2% |
| EPS growth | — | 138.5% | 29.0% | 11.3% | 115.7% | −1.6% | 21.7% | −2.2% | −36.4% |
| FCF growth | — | 153.2% | 68.5% | 28.0% | 120.9% | 3.5% | −2.2% | −25.1% | −36.1% |
| Share count change | — | 18.0% | 117.4% | 10.6% | 2.2% | −0.7% | 0.6% | −6.2% | −18.8% |
| Financial health | |||||||||
| Current ratio | — | 2.6x | 6.6x | 8.3x | 9.1x | 7.7x | 13.2x | 10.2x | 9.9x |
| Quick ratio | — | 2.4x | 6.3x | 7.8x | 8.7x | 7.2x | 12.5x | 9.4x | 8.8x |
| Capital allocation | |||||||||
| Capex / revenue | 0.4% | 0.4% | 0.4% | 0.2% | 0.3% | 0.3% | 0.1% | 0.2% | 0.3% |
| Stock comp / revenue | 4.6% | 1.9% | 1.0% | 6.2% | 3.3% | 5.4% | 4.8% | 4.2% | 3.0% |
| Payouts / FCF | — | — | — | 21.9% | 20.3% | 23.7% | 0.0% | 216.2% | 151.2% |
| Quality scores | |||||||||
| Piotroski F-score | — | — | 6.0 | 4.0 | 6.0 | 4.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | — | 8.5 | 13.5 | 15.8 | 17.3 | 16.6 | 21.0 | 19.0 | 18.9 |
| Accruals ratio | — | −17.9% | −0.7% | −1.6% | −2.6% | −3.6% | 2.8% | 5.9% | 1.1% |
Source: SEC EDGAR XBRL filings (CIK 0001742692). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
